Inhibrx EV/EBITDA
Что обозначает EV/EBITDA в Inhibrx?
EV/EBITDA Inhibrx, Inc. является N/A
Какое определение для EV/EBITDA?
EV / EBITDA - это стоимость предприятия, деленная на прибыль до вычета процентов, налогов, обесценивания и амортизации. При помощи неё измеряется, насколько дорогой является акция, и она более действительна для сравнения компаний, чем для соотношения цены и прибыли. Она измеряет цену (в форме стоимости предприятия), которую инвестор платит в пользу денежного потока компании (в форме EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA компаний в Health Care сектор на NASDAQ по сравнению с Inhibrx
Что делает Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Компании с ev/ebitda похож на Inhibrx
- Wishpond Technologies имеет EV/EBITDA из N/A
- Future Bright имеет EV/EBITDA из N/A
- GoldQuest Mining имеет EV/EBITDA из N/A
- Powercell Sweden Sk ,022 имеет EV/EBITDA из N/A
- O3 Mining имеет EV/EBITDA из N/A
- Tijaria Polypipes имеет EV/EBITDA из N/A
- Inhibrx имеет EV/EBITDA из N/A
- Kidsland International имеет EV/EBITDA из N/A
- Americas Car Mart имеет EV/EBITDA из N/A
- Reabold Resources Plc имеет EV/EBITDA из N/A
- Ausmex Mining имеет EV/EBITDA из N/A
- amalphi ag имеет EV/EBITDA из N/A
- Silver Range Resources имеет EV/EBITDA из N/A